FATE – Fate Therapeutics, Inc.
Float Short %
6.92
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
-0.01
EPS Last/This Y
0.49
EPS This/Next Y
-0.01
Price
1.08
Target Price
4.94
Analyst Recom
2
Performance Q
11.8
Relative Volume
0.35
Beta
2.22
Ticker: FATE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | FATE | 1.09 | 0.21 | 0.25 | 9083 |
| 2025-11-11 | FATE | 1.115 | 0.21 | 0.00 | 9081 |
| 2025-11-12 | FATE | 1.04 | 0.21 | 1.22 | 9042 |
| 2025-11-13 | FATE | 0.9814 | 0.21 | 0.00 | 9126 |
| 2025-11-14 | FATE | 0.9601 | 0.22 | 0.00 | 9053 |
| 2025-11-17 | FATE | 0.9901 | 0.22 | 0.02 | 9006 |
| 2025-11-18 | FATE | 1.025 | 0.21 | 0.07 | 9067 |
| 2025-11-19 | FATE | 1.06 | 0.21 | 66.67 | 9229 |
| 2025-11-20 | FATE | 1.01 | 0.24 | 0.44 | 9415 |
| 2025-11-21 | FATE | 1.025 | 0.22 | 0.28 | 9304 |
| 2025-11-24 | FATE | 1.085 | 0.13 | 1.62 | 5040 |
| 2025-11-25 | FATE | 1.055 | 0.16 | 121.80 | 5139 |
| 2025-11-26 | FATE | 1.09 | 0.29 | 0.73 | 5752 |
| 2025-12-01 | FATE | 1.025 | 0.38 | 3.85 | 6549 |
| 2025-12-02 | FATE | 1.005 | 0.47 | 0.00 | 7512 |
| 2025-12-03 | FATE | 1.07 | 0.47 | 0.01 | 7588 |
| 2025-12-04 | FATE | 1.11 | 0.48 | 0.22 | 7442 |
| 2025-12-05 | FATE | 1.07 | 0.48 | 0.50 | 7452 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | FATE | 1.09 | 29.5 | - | -1.14 |
| 2025-11-11 | FATE | 1.12 | 29.5 | - | -1.14 |
| 2025-11-12 | FATE | 1.03 | 29.5 | - | -1.14 |
| 2025-11-13 | FATE | 0.98 | 29.5 | - | -1.14 |
| 2025-11-14 | FATE | 0.96 | 42.6 | - | -1.14 |
| 2025-11-17 | FATE | 0.98 | 42.6 | - | -1.13 |
| 2025-11-18 | FATE | 1.02 | 42.6 | - | -1.13 |
| 2025-11-19 | FATE | 1.05 | 42.6 | - | -1.13 |
| 2025-11-20 | FATE | 1.00 | 42.6 | - | -1.13 |
| 2025-11-21 | FATE | 1.02 | 37.6 | - | -1.15 |
| 2025-11-24 | FATE | 1.08 | 37.6 | - | -1.15 |
| 2025-11-25 | FATE | 1.06 | 37.6 | - | -1.15 |
| 2025-11-26 | FATE | 1.09 | 37.6 | - | -1.15 |
| 2025-12-01 | FATE | 1.02 | 37.6 | - | -1.15 |
| 2025-12-02 | FATE | 1.00 | 37.6 | - | -1.15 |
| 2025-12-03 | FATE | 1.08 | 37.6 | - | -1.15 |
| 2025-12-04 | FATE | 1.11 | 37.6 | - | -1.15 |
| 2025-12-05 | FATE | 1.08 | 37.6 | - | -1.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | FATE | -0.41 | -12.83 | 6.88 |
| 2025-11-11 | FATE | -0.41 | -12.83 | 6.88 |
| 2025-11-12 | FATE | -0.41 | -12.83 | 6.23 |
| 2025-11-13 | FATE | -0.41 | -12.83 | 6.23 |
| 2025-11-14 | FATE | -0.41 | -12.83 | 6.23 |
| 2025-11-17 | FATE | -0.41 | -7.99 | 6.23 |
| 2025-11-18 | FATE | -0.41 | -7.99 | 6.23 |
| 2025-11-19 | FATE | -0.41 | -7.99 | 6.23 |
| 2025-11-20 | FATE | -0.41 | -7.99 | 6.23 |
| 2025-11-21 | FATE | -0.41 | -7.99 | 6.23 |
| 2025-11-24 | FATE | -0.41 | 0.84 | 6.23 |
| 2025-11-25 | FATE | -0.41 | 0.84 | 6.23 |
| 2025-11-26 | FATE | -0.41 | 0.84 | 6.92 |
| 2025-12-01 | FATE | -0.41 | 1.06 | 6.92 |
| 2025-12-02 | FATE | -0.41 | 1.06 | 6.92 |
| 2025-12-03 | FATE | -0.41 | 1.06 | 6.92 |
| 2025-12-04 | FATE | -0.41 | 1.06 | 6.92 |
| 2025-12-05 | FATE | -0.41 | 1.06 | 6.92 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.27
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
-0.41
Institutional Transactions
1.06
Beta
2.22
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
Fair Value
Quality Score
13
Growth Score
23
Sentiment Score
15
Actual DrawDown %
99.1
Max Drawdown 5-Year %
-99.4
Target Price
4.94
P/E
Forward P/E
PEG
P/S
17.45
P/B
0.53
P/Free Cash Flow
EPS
-1.32
Average EPS Est. Cur. Y
-1.15
EPS Next Y. (Est.)
-1.16
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2187.11
Relative Volume
0.35
Return on Equity vs Sector %
-93.6
Return on Equity vs Industry %
-78.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading